Brief Report: Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy

A patient in whom diarrhea had developed 4 months after BCMA-directed CAR T-cell therapy for myeloma was found to have an indolent CD4+ lymphoma of the small intestine containing the CAR gene product.

​   The New England Journal of Medicine: Search Results in Hematology/Oncology